A retrospective study of 101 patients with LMD who underwent CSF CTC quantification with the CellSearch® platform could predict a doubling of mortality risk at the optimal cut-off of ≥61 CSF CTCs/3 mL [48]. This evidence concerns the gene CSF2 and Langer mesomelic dysplasia.